EN
中文 EN
Company News
Home >Newsroom >Company News
ALL
2026
2025
2024
2023
2022
2021
2020
2019
2018
2016
2015
2014
2013
2012
2007
2026.07.21
CanSinoBIO Signs PCV13i LOI with Pakistani Partner to Expand Vaccine Collaboration in South Asia
2026.07.19
CanSinoBIO's Menhycia® Application Accepted by China's NMPA for Expanded Use in Population Aged 3 Months to 17 Years
2026.06.25
CanSinoBIO's MCV4 Receives Registration Approval in Argentina, Expanding Global Reach
2026.06.10
CanSinoBIO Holds 2025 Annual General Meeting of Shareholders
2026.05.25
CanSinoBIO Advances Pneumococcal Disease Prevention Strategy with Initiation of Phase I/II Trial for PCV24
2026.05.11
CanSinoBIO's Td5cp Vaccine Granted Priority Review by NMPA, Advancing Life-Course Immunization Strategy
2026.04.10
Breaking News | CanSinoBIO's Next-Generation Three-Component DTcP Vaccine Tripecia® Officially Approved
2026.03.31
CanSinoBIO's CEO Xuefeng Yu on Bloomberg: Building Long-Term Competitiveness Through Innovation and Global Vision
2026.03.13
CanSinoBIO Highlights Participation at the VIF World 2026, Discusses Global Accessibility of Innovative Vaccines
2026.03.05
CanSinoBIO Manufacturing Site Receives Malaysia NPRA PIC/S GMP Certificate, Advancing the Global Deployment of Innovative Vaccines
12